Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
29 May 2018 | Story Rulanzen Martin | Photo Charl Devenish
Africa Day Memorial Lecture explores future of statues
From the left are: Dr Stephanie Cawood, Acting Director of the CGAS; Prof Heidi Hudson, Dean of the Faculty of the Humanities; Prof Prakash Naidoo, Vice-Rector: Operations; and Dr Rahul Rao.
Read Lectures here

Drawing from different international perspectives on the topic of historical statues, the importance of debate surrounding the future of these symbols resounded at the 10th Annual Africa Day Memorial Lecture. 

The lecture was hosted on 23 May 2018 by the newly renamed Centre for Gender and Africa Studies and was presented by Dr Rahul Rao from the SOAS University of London, where he is a senior lecturer in Politics. 

“I am very excited about my trip to South Africa and to be here among you. This is my first trip to South Africa, and it is very exciting and also a little bit emotional for me, particularly because I got my first passport in 1984 when I was six years old, and it said – valid for travel to all countries except the Republic of South Africa. You know why that was the case.”

“I salute all of you for the transformation that has been affected in this country, and I think Africa Day is the perfect occasion to celebrate the transformation.”  

Student activism through #MustFall movements
“I first heard in March 2015 that students from the University of Cape Town have begun demonstrating to take down the statue of Cecil John Rhodes and have it removed from their campus, and a bit later, students from the University of Oxford in the United Kingdom followed suit. At first, I felt some guilt having been a Rhodes Scholar from 2001 to 2004, because you must embody the values of Cecil John Rhodes,” Dr Rao said.

“I have watched from afar the events that have taken place here, for example, the #RhodesMustFall Movement, and the reverberation of these events in other places; I mean, the way these events travel,” he said.

Students in Cape Town, Oxford, and Bloemfontein are doing something concrete and collective to dismantle the legacy of colonialism and Apartheid. “I feel connected to these events, even if I am far away.”

International perspective on historical statues
In both SA and the UK, the call for iconography decolonisation was accompanied and soon overtaken by different accounts. It also gives a broader and different perspective on how statues can be used to achieve racial or social dominance. 

One of the many examples he used, was the ambush against Confederate Statues in the American South. These statues are symbols of upholding a white supremacist ideology in the South. The Confederate States of America was the predecessor to the current United States of America.

He also spoke about the temporalities of statues, the decolonisation and recolonisation, as well as the aesthetics of statues, among other things. “Statues don't need permission to thrust itself upon us. They demand attention,” Dr Rao said. This is because statues are placed in the centre of public spaces but are also vulnerable and exposed. 

He left the audience with some questions on what to do with statues that are taken down, and who to erect new statues for.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept